Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)

NCT01854645 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2103

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: GFF MDI
DRUG: GP MDI
DRUG: FF MDI
DRUG: Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)
DRUG: Placebo MDI

Sponsor

Pearl Therapeutics, Inc.